David Linetsky, Senior Vice President of Life Sciences at Phreesia, Inc. (NYSE:PHR), has sold 1,100 shares of the company's common stock, according to a recent SEC filing. The shares were sold at a price of $20.49 each, totaling $22,539. Following the transaction, Linetsky retains direct ownership of 200,207 shares. This sale was conducted under a 10b5-1 trading plan adopted by Linetsky on July 18, 2024.
In other recent news, healthcare software company Phreesia Inc . has been making significant strides in its financial performance. The firm reported a 19% year-over-year increase in second-quarter revenue, slightly exceeding expectations, and a positive EBITDA of $7 million, a marked improvement from a loss of $12 million in the same quarter of the previous year. This led to an upward revision of the EBITDA forecast for fiscal year 2025, suggesting an improvement in profit margins to 7%.
Baird, a financial services firm, raised its price target for Phreesia's shares to $34, maintaining an Outperform rating on the stock. Similarly, Truist Securities, Piper Sandler, Canaccord Genuity, and Needham have expressed positive outlooks on Phreesia's financial performance, maintaining their respective price targets and ratings.
Phreesia has also provided new guideposts for client growth and revenue per client for fiscal years 2025 to 2026, signaling a shift toward sustained profitable growth. The company's recent financial results and future growth indicators have contributed to the confidence expressed by these analyst firms in Phreesia's financial trajectory. These are the recent developments investors should note.
InvestingPro Insights
As David Linetsky reduces his stake in Phreesia, Inc. (NYSE:PHR), investors might be curious about the company's current financial health and market position. According to InvestingPro data, Phreesia's market capitalization stands at $1.12 billion, with a revenue of $389.96 million for the last twelve months as of Q1 2023. The company has shown strong revenue growth of 22.1% over the same period, indicating potential for expansion in the healthcare technology sector.
However, InvestingPro Tips reveal that Phreesia is not currently profitable, with a negative P/E ratio of -10.92. This aligns with the tip that analysts do not anticipate the company will be profitable this year. Despite this, Phreesia maintains a moderate level of debt, which could provide some financial flexibility as it pursues growth opportunities.
The stock's recent performance has been challenging, with InvestingPro data showing a one-month price total return of -16.87%. This downturn is reflected in an InvestingPro Tip suggesting the stock's RSI indicates it may be in oversold territory, potentially presenting a value opportunity for investors who believe in the company's long-term prospects.
For those seeking a more comprehensive analysis, InvestingPro offers 7 additional tips that could provide deeper insights into Phreesia's financial situation and market outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.